Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

Journal Article (Journal Article;Multicenter Study)

Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was conducted to examine the efficacy and toxicities of sunitinib in metastatic CRPC progressing after 1-2 previous chemotherapy regimens including docetaxel. The primary objective was clinical progression-free survival (PFS) with a 12-week PFS > or = 30% assumed to be of interest. Secondary objectives included prostate-specific antigen (PSA) response, modulation of PSA kinetics, objective response, quality of life, pain, survival, and toxicities. Sunitinib 50 mg daily was administered orally on days 1-28 of each 6-week cycle. Patients were treated to a maximum of 8 cycles or until clinically progressive disease or intolerable toxicity.

Full Text

Duke Authors

Cited Authors

  • Sonpavde, G; Hutson, TE; Berry, WR; Boehm, KA; Asmar, L

Published Date

  • September 2008

Published In

Volume / Issue

  • 6 / 2

Start / End Page

  • 134 - 137

PubMed ID

  • 18824440

International Standard Serial Number (ISSN)

  • 1558-7673

Digital Object Identifier (DOI)

  • 10.3816/CGC.2008.n.023


  • eng

Conference Location

  • United States